Call Us      +44 (0)20 70961222

Medical Chemistry

JOIN OUR USA WEST COAST 2018 STRATEGY MEETING


31st October 2018 | The Hyatt Regency Airport, San Francisco, USA

OUR UNIQUE FORMAT

The Medicinal Chemistry Roundtable Discussions Strategy Meeting is free to attend for qualified end-users.These include Senior Executives of Early Drug Discovery (from medium to large Pharma, Biopharma and Biotech players) as well as thought leaders from Academia and regulatory authorities.

Thought leaders who will benefit from attending include CXOs, EVPs, SVPs, VPs, Executive Directors, Directors and Global Heads responsible for:
– Chemistry, Immunology Chemistry, Chemistry Technologies, Medicinal and Innovative Chemistry, Drug Discovery & DMPK, Chemical and Molecular Therapeutics, Chemical Development, Biochemistry & Molecular Pharmacology, Computational and Structural Chemistry, Biochemistry.

FACILITATORS
Simon Bailey

Simon Balley

Senior Vice President

Intercept Pharmaceuticals

Jagath Junutula

Jagath Reddy Junutula

Vice President

Cellerant Therapeutics

Ken Brameld

Ken Brameld

Vice President, Drug Discovery

Principia Biopharma

Robert Burk

Robert Burk

Executive Director

Allergan

Steve Potts

Steve Potts

Vice President, Global Medical and Diagnostic Affairs

Ignyta, Inc

Dave Wustrow

Dave Wustrow

Vice President, Drug Discovery

FLX Bio

Wendy Young

Wendy Young

Vice President, Discovery Chemistry

Genentech

Alan Northrup

Alan Northrup

Executive Director, Head of Chemistry

Merck

ADVISORY BOARD
Klaus-Urbahns-3-270×260

Klaus Urbahns

Senior Vice President, Discovery Technologies

Merck Group

Darryl-McConnell-1-270×260

Darryl McConnell

Vice President, Discovery Research Site Head, Austria

Boehringer Ingelheim

Jean-Kim-Medchem

Jean Kim

Senior Vice President, Chemistry

Kadmon

WHAT TO EXPECT
roundtable
Interactive Roundtable Discussions

Attendees can proactively share and ask questions to their peers about the success of their work in an informal setting.

one to one copy
Director level one-to-one meetings

We provide opportunities to engage with one another in our strategy meeting in a series of pre-arranged business meetings by interacting face to face.

agenda
Tailor-fit and Personalized Agenda

Being able to experience different sessions is what makes our event unique that’s why our attendees can personalize and select sessions they want to participate in.

netwkorking copy
Networking Opportunities

Several networking opportunities are in store for attendees to connect and build new relationships with their peers through luncheons, cocktails and informal introductions.

MEDICINAL CHEMISTRY

STRATEGY MEETING WEST COAST USA 2018








***The information you provided in this website is confidential and the company will strictly forbidden to share any part of these information with any third party without a written consent of the sender.

BECOME SPONSOR

If you are an exciting start-up trying to get your innovation in front global heads from the leading Pharmaceutical companies, or a mature market-leading conglomerate with legacy solutions trying to stay one step ahead of the competition – we are here to help!

WHAT PEOPLE SAY

Medicinal Chemistry Strategy Meeting US East Coast 2016

John Apathy, Vice President, R&D informatics, Celgene

Lars Branden, Senior Director,Informatics R&D Division, Retro Screen Virology Ltd.

Dominic Clark , Industry Programme Manager, EMBL-EBI

Yike Guo, Director Data Science Institude, Imperial College London

John Wise, Executive Director, Pistoia Alliance

Abel Ureta-Vida, CEO, Eagle Genomics

Alexander Scheer, Deputy Head of Research, Pierre Fabre

Jerome Wojcik , CEO, Quartz Bio

Oleksandr Otava, Head Of Scientific IT, Affiris AG

Sowmyanarayan Srinivasan, Director R&D Practise,Global Delivery Leader Discovery

Yaron Turpaz

Chief Information Officer

Its nice because they basically allowed people to engaged to discussions and questions. Academic and industry is very nice and informative

Ivan John Clement

Data Scientist - R&D

Its good because you really get the people to talk. They are willing to share their knowledge, the juniors are very eager to learn.

Raghuraman Gopal

Manager Quality Assurance

The format is the beginning of breakthrough and integration, the level of delegates is very good and excellent, they learn a lot.

Dadabhai Singh

Founder & President

The kind of interaction is very interactive

Steve Rozen

Director & Professor

Because of diversity we really districts the points and all. People are very diversity and thoughtful in a round table.

THE VENUE

HYATT REGENCY
SAN FRANCISCO AIRPORT


Address

1333 Old Bayshore Hwy, Burlingame, CA 94010, USA


Phone

+1 650-347-1234

OUR MEDIA PARTNERS




Klaus-Urbahns-3-270×260

Klaus Urbahns

Senior Vice President, Discovery Technologies

Merck Group

Klaus Urbahns has more than 20 years of experience in the biopharmaceutical industry. He is Senior Vice President, Head of the Discovery Technology Platform at MerckSerono with laboratories in the US, Israel and Germany. His team’s role is to generate small molecule drug candidates and therapeutic proteins. Prior to joining Merck, Klaus served at AstraZeneca in the UK and Sweden. He started his professional career at Bayer, holding positions in Germany and Japan. Klaus is member of the advisory board of the Lead Discovery Center (LDC) and the Medicines for Malaria Venture (MMV). Klaus studied chemistry at the universities of Kiel, Freiburg and Frankfurt.

Darryl-McConnell-1-270×260

Darryl McConnell

Vice President, Discovery Research Site Head, Austria

Boehringer Ingelheim

Darryl McConnell is currently Research Site Head and Head of Medicinal Chemistry at Boehringer-Ingelheim Regional Centre Vienna, Austria where the main research focus is oncology. Darryl commenced his career with Boehringer-Ingelheim in 2002 as a Research Laboratory Head and is in his current role since 2015.

Prior to this Darryl has worked for Intervet in Vienna from 2001, for Biota Holdings Ltd in Melbourne, Australia from 1999 in the area of respiratory viruses and Chiron Technologies in Melbourne from 1997.

Darryl McConnell received his Bachelor of Science with First Class Honours in 1991 with Professor John Elix at the Australian National University in Canberra. He performed his PhD at the University of New South Wales in Sydney with Professor David Black for which he was awarded the Cornforth Medal for the best chemistry PhD thesis in Australia for that year. Following this he performed a 2 year Postdoctoral study at the University of Sydney with Professor Leslie Field in organometallic chemistry.

Darryl’s interest lie in the areas of cancer cell directed and immune cell directed therapies for cancer as well as protein crystallography and protein NMR, fragment based and structure based drug discovery, drug discovery software , agile methods in drug discovery and natural product inspired medicinal chemistry.

Jean-Kim-Medchem

Jean Kim

Senior Vice President, Chemistry

Kadmon

Jean Kim is a Senior V.P. of Chemistry at Kadmon where she currently leads the discovery of small molecule therapeutic agents for Oncology, Autoimmunity, and Anti-infective diseases.  She directed numerous research programs at Merck and Wyeth Laboratories and has worked in the field of Medicinal Chemistry Research for over 20-years, towards finding therapies for Metabolic Syndrome and Diabetes, and Neurological disorders. Jean is a co-inventor of Nemonoxacin, an antibiotic marketed for the treatment of community-acquired pneumonia (CAP). Jean received her Ph.D. in organic chemistry from University of Illinois, at Champaign-Urbana, and completed post-doctoral research in University of Basel, Switzerland after receiving her B.S. in chemistry from Cornell University.

Magnus-Walter-1-270×260

Magnus Walter

Chief Scientific Officer, Head of Chemistry, Eli Lilly and Company

JMagnus Walter received a Master’s degree in Chemistry from the University of Bonn in Germany and a doctorate from the University of Oxford for his work on resistance against ß-lactam antibiotics. After starting his industrial career at Zeneca in 1998 as chemistry team leader he has worked for Eli Lilly since 2001 based at Lilly’s Erl Wood Research Centre in the UK. In 2012 he become Head of Department at Lilly’s UK Research Centre leading a group of approximately one hundred chemists focused on drug discovery in the areas of neurodegeneration, pain and endocrinology. Since 2014 he is Chief Scientific Officer in Medicinal Chemistry with global portfolio responsibility of Lilly’s chemistry research in the area of Neurodegeneration.

2017-08-15-260×260

Sergio Lociuro

Chief Scientific Officer, Bioversys AG

Sergio received his Laurea degree in Chemistry at the University of Rome in 1981. After a two-year postdoctoral fellowship at the Italian CNR, he moved to UNB, Canada, where he received his Ph.D in 1987. In his almost 30 years experience in major pharmaceutical companies and SMEs, Sergio has held positions such as Director of Medicinal Chemistry and International Project Leader in GSK, Head of PEM in Polyphor, Head of Research in Arpida and CSO to C10-Pharma and Adenium. Founder of THOT consulting, a consulting firm in DD, he is currently CSO to BioVersys. His experience spans from early drug discovery to the conduction of Phase I studies.

joel_richard

Dr Joël Richard

Senior Vice President, Peptides, Ipsen

Dr Joël Richard is presently leading all the Pharmaceutical Development activities of Peptides & Small Molecules for the Ipsen Company. Dr Richard has got his PhD in Materials Science/Colloids & Interface Science from University of Paris VI. He has more than 25 years of experience in chemistry and biopharmaceutical R&D, including several global senior leadership positions in various Biotech and Pharma companies, such as Ipsen, Merck Serono, Serono and Ethypharm. Dr Richard has focused his research activity on innovative drug delivery especially for injectable protein and peptide formulations. Dr Richard has published 68 peer-reviewed scientific papers, 8 book chapters and 2 editorials in various fields. He is the author of more than 120 international communications and 53 patent families.

Bayard-Huck1-270×260

Bayard R. Huck

Vice President, Global Head of Medicinal Chemistry, Merck

Bayard Huck is currently the Global Head of Medicinal Chemistry at Merck Biopharma (subsidiary of Merck KGaA). Bayard received his Ph.D. in Organic Chemistry from the University of Wisconsin – Madison. His medicinal chemistry experience ranges from driving multiple small molecule programs from concept to clinic, to leading multiple programs to clinical proof of concept. Currently, as Global Head of Medicinal Chemistry, Bayard oversees the medicinal chemistry efforts at Merck Biopharma in support of Immunology, Immuno-Oncology, and Oncology therapeutic areas.

Thorsten-Thormann-270×260

Thorsten Thormann

Vice President, Research, LEO Pharma

Thorsten Thormann is Vice President of Research in LEO Pharma A/S and has over 15 years of experience within biomedicine and drug research. Prior to being Vice President of Research, Thorsten has held a number of leadership positions within LEO Pharma aiming to build translational drug discovery platforms in dermatology as well as refocusing the early formulation and CMC to build a platform for product improvements based on usability and patient driven innovation. Thorsten Thormann has a MSc in Chemistry from the University of Roskilde and a PhD in Protein Biology from the University of Copenhagen.

tobias_gabriel

Tobias Gabriel

Global Head, External Science & Drug Discovery, Global Discovery Chemistry, Novartis

Tobias Gabriel is the Global Head of External Drug Discovery at Global Discovery Chemistry, Novartis Institutes for BioMedical Research. Prior to his current role Tobias was Head of Oncology Chemistry, Basel and Shanghai. Tobias joined Novartis seven years ago from Roche where he held positions of increasing responsibility in Medicinal Chemistry in Palo Alto and as Director of Research Strategy in Basel. Tobias studied Chemistry in Berlin and completed his Ph.D. in Organic Chemistry in Munich, followed by postdoctoral studies in nanotechnology at the Hebrew University of Jerusalem.

tobias_gabriel

Tobias Gabriel

Global Head, External Science & Drug Discovery, Global Discovery Chemistry, Novartis

Tobias Gabriel is the Global Head of External Drug Discovery at Global Discovery Chemistry, Novartis Institutes for BioMedical Research. Prior to his current role Tobias was Head of Oncology Chemistry, Basel and Shanghai. Tobias joined Novartis seven years ago from Roche where he held positions of increasing responsibility in Medicinal Chemistry in Palo Alto and as Director of Research Strategy in Basel. Tobias studied Chemistry in Berlin and completed his Ph.D. in Organic Chemistry in Munich, followed by postdoctoral studies in nanotechnology at the Hebrew University of Jerusalem.

stephan-zahn

Stephan Zahn

Director, Medicinal Chemistry, Boehringer-Ingelheim

Born in Wilhelmshaven, Germany. Studies of Chemistry at the University of Marburg and Edinburgh from 1992 to 1997. Diploma with Prof. Dr. R. W. Hoffmann in 1997. Received PhD in 2001 under the supervision of Prof. Dr. B. Breit working in Marburg and Heidelberg on Stereoselective Hydroformylation for the construction of Stereotriads in Polyketides.
In 2002 joined Boehringer Ingelheim in Vienna to build up the MedChem Facilities for Oncology research. Experience in drug discovery from early stage to clinical candidates. In 2013 appointed Director at Boehringer Ingelheim in Vienna taking responsibility for drug discovery strategy, MedChem and organic synthesis.